Daniel Marsh

Daniel Marsh

Senior Markets Analyst

Daniel Marsh is a senior markets analyst at StockTi with over 12 years of experience covering U.S. and global equity markets. He holds a CFA charter and previously worked as an equity research associate at a major Wall Street firm. Daniel specializes in macroeconomic analysis, market trends, and cross-sector investment themes. His work focuses on translating complex market data into actionable insights for individual and institutional investors.

Markets, Economy, Analysis 5,966 articles

Articles by Daniel Marsh

Bernstein Lifts Microsoft Target to $660 on Azure Momentum
Analysis

Bernstein Lifts Microsoft Target to $660 on Azure Momentum

Bernstein raised its Microsoft price target to $660, citing surging Azure growth and a shift in AI spending risk perception. The stock remains at a discount to historical valuation.

MSFT
Small Business Optimism Hits 11-Month High, Labor Shortages Persist
Economy

Small Business Optimism Hits 11-Month High, Labor Shortages Persist

U.S. small business optimism climbed to an 11-month high in July, but labor shortages and rising borrowing costs could temper growth prospects.

SPY
Riot Platforms Soars on $9.1B AI Data Center Deal with Anthropic
Markets

Riot Platforms Soars on $9.1B AI Data Center Deal with Anthropic

Riot Platforms (RIOT) surged over 22% after disclosing a $9.1 billion AI data center lease with Anthropic, marking a major pivot toward high-value infrastructure.

RIOT AMD MS
Chevron Surges 4.5% as Oil Rally Tightens Analyst Upside
Markets

Chevron Surges 4.5% as Oil Rally Tightens Analyst Upside

Chevron (CVX) shares rose 4.48% to $194.91 as oil prices rallied on stalled Iran talks, but the average analyst target now offers just 6.4% upside.

CVX XOM COP USO MSFT
RBA Holds Cash Rate at 4.35%, Cuts Inflation Forecast, Sees Higher Jobless Rate
Economy

RBA Holds Cash Rate at 4.35%, Cuts Inflation Forecast, Sees Higher Jobless Rate

The RBA left the cash rate at 4.35% unanimously, lowered December inflation forecast to 3.3%, and lifted unemployment outlook to 4.5%.

CBAUF
Teledyne to Acquire Varex Imaging in $1.1B All-Cash Deal
Analysis

Teledyne to Acquire Varex Imaging in $1.1B All-Cash Deal

Teledyne Technologies will acquire Varex Imaging for $18.90 per share in cash, valuing the X-ray components maker at roughly $1.1 billion. The deal offers a 52% premium and is expected to close in early 2027.

TDY VREX
Intel's $15B Equity Raise Fuels Foundry Expansion Amid AI Surge
Analysis

Intel's $15B Equity Raise Fuels Foundry Expansion Amid AI Surge

Intel plans a $15B common stock offering, about 3.1% dilution, to fund 75% of 2026 capex. The move capitalizes on a stock surge driven by AI demand.

INTC AMD NVDA TSM JPM GS MS C
RBC, BMO Sell Moneris in C$2B Deal, Keep Payment Ties
Markets

RBC, BMO Sell Moneris in C$2B Deal, Keep Payment Ties

RBC and BMO have agreed to sell Moneris Solutions to Francisco Partners for C$2 billion, with RBC expecting an after-tax gain of about C$475 million. The banks will maintain long-term referral agreements.

RY BMO
China's Inflation Slowdown Widens Factory Margin Squeeze
Economy

China's Inflation Slowdown Widens Factory Margin Squeeze

China's July inflation missed expectations, with CPI up 0.5% and PPI at 3.5%. The 5.6-point gap between factory-gate and consumer prices highlights ongoing margin pressure.

FXI MCHI
Take-Two Climbs as GTA VI Hype Fuels $8.1B Bookings Forecast
Markets

Take-Two Climbs as GTA VI Hype Fuels $8.1B Bookings Forecast

Take-Two Interactive (TTWO) shares jumped 2.87% to $253.57 on strong volume, extending gains after Q1 results beat guidance. The company reaffirmed its fiscal 2027 bookings forecast of $8.0-$8.2 billion, driven by anticipation for Grand Theft Auto VI.

TTWO HAS MAT
Target Hits 52-Week High as Back-to-School Strategy Gains Traction
Analysis

Target Hits 52-Week High as Back-to-School Strategy Gains Traction

Target (TGT) closed at a 52-week high of $152.02, up 1.55%, as investors bet on a strong back-to-school season. The stock now trades 12% above analysts' average target, raising stakes for upcoming earnings.

TGT AMZN WMT COST
Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production
Analysis

Bristol Myers Unveils $2.3B Houston Facility for Flexible Drug Production

Bristol Myers Squibb (BMY) will build a $2.3 billion drug-manufacturing campus in Houston, supporting small molecules, biologics, and antibody-drug conjugates, with nearly 500 skilled jobs.

BMY LLY JNJ RHHBY AZN